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Abstract
Human dopamine transporter gene (DAT1 or SLC6A3) has been associated with various brain-related diseases and behavioral
traits and, as such, has been investigated intensely in experimental- and clinical-settings. However, the abundance of research
data has not clarified the biological mechanism of DAT regulation; similarly, studies of DAT genotype-phenotype associations
yielded inconsistent results. Hence, our understanding of the control of the DAT protein product is incomplete; having this
knowledge is critical, since DAT plays the major role in the brain’s dopaminergic circuitry. Accordingly, we reevaluated the
genomic attributes of the SLC6A3 gene that might confer sensitivity to regulation, hypothesizing that its unique genomic
characteristics might facilitate highly dynamic, region-specific DAT expression, so enabling multiple regulatory modes. Our
comprehensive bioinformatic analyzes revealed very distinctive genomic characteristics of the SLC6A3, including high inter-
individual variability of its sequence (897 SNPs, about 90 repeats and several CNVs spell out all abbreviations in abstract) and
pronounced sensitivity to regulation by epigenetic mechanisms, as evident from the GC-bias composition (0.55) of the
SLC6A3, and numerous intragenic CpG islands (27 CGIs). We propose that this unique combination of the genomic features
and the regulatory attributes enables the differential expression of the DAT1 gene and fulfills seemingly contradictory
demands to its regulation; that is, robustness of region-specific expression and functional dynamics.
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Introduction
Dopamine (DA) neurotransmission underlies core brain
functions, including locomotion, behavior, cognition and moti-
vation; consequently, disruption in dopamine signalling gives rise
to various neuropsychiatric disorders and conditions i.e.,
Parkinson’s disease, schizophrenia, attention deficit/hyperactiv-
ity disorder (ADHD) and addiction [1]. A key player in
regulation of DA signalling is the dopamine transporter (DAT),
it modulates the dynamics and the levels of DA in the synaptic
cleft by recycling extracellular DA back into the presynaptic
terminal. Alterations in the DAT availability in the brain directly
affects the concentration of synaptic DA and the kinetics of its
reuptake [2].
DAT expressed in the brain in a region-specific manner, most
abundantly in the striatum (the mesostriatal DA pathway), where
its concentration is more than ten fold higher than in the frontal
regions (Figure 1A and [3]). Even in the same brain region, DAT
expression significantly differs among individuals, reflecting high
phenotypic heterogeneity (Figure 1B shows actual measures of the
amount of the DAT1 mRNAs in the midbrain; see also [4]). DAT
expression is highly dynamic: the brain’s DAT level adjusts to
accommodate DA signaling, decreasing when DA release is low
and increasing when DA release is high [5]. They change
markedly in response to drugs [6], salient stimuli [6], environ-
mental factors [7], and pathogens [8]. DAT expression alters
throughout the life span; first detectable in developing brain
relatively late, starting from 32 gestation weeks, the DAT level
reaches maximum during adolescence, and then gradually
decreases at an estimated rate of 5–6% per decade [9].
The possibility that the individual variations of basal DAT levels
in the brain are due to genetic differences focused much attention
on the DAT1 gene (SLC6A3). It has been rigorously investigated in
numerous clinical studies that aimed at revealing an association
between the DAT1 genotype and the risks for various brain-related
diseases (reviewed in [7,10]). By and large, these attempts had
narrow scope: most focused on a single DAT1 polymorphism, the
functional 39-UTR VNTR (variable number of tandem repeats)
[11]. This polymorphism was associated with numerous neuro-
logical- and psychiatric disorders, including ADHD [7], cocaine-
induced paranoia [12], tobacco smoking [13], and alcohol
dependence [14], however, the findings have not been consistently
replicated and most of the studies reported no effect of this
polymorphism on neurophysiologic and psychiatric measures.
Contribution of the 39-UTR VNTR to differences in density and
affinity of DAT was also investigated by several imaging studies;
several studies provided some evidence of support [15], though the
others did not [16].
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etiology of neuropsychiatric disorders; in most instances such
disorders arise through the interactions of genetic and environ-
mental factors (reviewed in [17]). The environment is a potent
genetic modifier, influencing gene expression via epigenetic
mechanisms. Ubiquitous epigenetic mechanisms represent an
essential element of normal development and maturation.
Aberrant epigenetic processes can cause maladaptive changes,
(gene dys-regulations and dys- functions) and consequently lead to
disease. In the brain, in contrast to somatic tissues, epigenetic
processes remain active throughout the lifespan: they ultimately
are involved in the maintaining brain functions, enabling adaptive
plasticity and the ability to accommodate varying environmental
challenges [18]. The fidelity of epigenetic processes is critical for
the human brain since its development creates enormously
complex biological patterning. Consequently, it is most susceptible
to aberrant activity of epigenetic modifiers: epigenetic dysregula-
tion is implicated in pathogenesis of a variety of brain-related
diseases, including mental retardation and complex psychiatric
disorders [19].
The intricate pattern of DAT regulation points to its control by
epigenetic mechanisms. Indeed, experimental and clinical studies
Figure 1. Variability of the dopamine transporter. A - DAT distribution in the brain. Averaged DVR [
11C]cocaine image at the level of the
striatum and ROI measures of DAT availability in caudate and putamen. Values represent means6standard deviations across 14 healthy men. B - DAT
availability in the striatum of healthy controls of different ages. Measures were obtained with PET and [
11C]cocaine and quantified as Bmax/Kd (using
Logan plots for irreversible systems). Note the range of variation in DAT availability across individuals.
doi:10.1371/journal.pone.0011067.g001
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from animal models demonstrated that environmental insults
during embryonic stage trigger changes in DAT level and delay
the development of plasticity in the mesolimbic dopamine system
[20] while in humans, early developmental exposure (in utero
exposure to tobacco smoke) contributes to the risks and the
pathogenesis of ADHD [7].
Currently many research groups are intent on unraveling the
mechanisms regulating DAT availability in the brain and on
identification of the genetic determinants that are involved in the
SLC6A3 control. Disparities in the results of traditional genetic
studies of the DAT1 genotype-phenotype relationship and
evidence for gene-environment interaction call for a novel
approach to studying the SLC6A3 gene variations accounting for
epigenetic mechanisms. We concentrated on developing a novel
regulatory paradigm for the SLC6A3, wherein genetic- and
epigenetic features are interconnected. Considering the facts
about the human DAT1 expression (summarized above), we
hypothesize that it has unique genomic features that provide a
basis for variable epigenetic sensitivity. Under this assumption, the
individual variations in the DAT1 gene sequence can directly affect
its epigenetic potential, so that we might construe large inter-
individual differences in brain’s DAT level as phenotypic
manifestations of the combinatorial interplay of the DAT1
haplotype and epigenetic marks that jointly regulate the DAT.
Empirical evidence supports our hypothesis; thus, the study of the
effect of developmental exposure to tobacco smoke clearly
demonstrated the risks of developing ADHD and the severity of
the disease depends on the DAT1 genotype [7]. Likewise, the
DAT1 genotype moderates the correlation between the risk for
ADHD and early childhood adversity (institutional deprivation)
[21].
To elaborate our hypothesis and to gain supporting theoretical
evidence, we undertook a bioinformatic analysis of the SLC6A3
locus using various genomic databases and computational
analytical tools available via public domains (Table 1). Knowing
that different software used to analyze same functional category
are based on different algorithms and used different set of
assumptions, and that random selection of one computational
approach over another could bias results and introduce errors of
interpretation, whenever possible, we applied several non-
redundant programs in the same analysis. We selected the
programs best suited to perform tasks and then ran them and
compared their outputs to compile exhaustive results. If, however,
the outputs obtained by different application were similar results,
we choose a representative one to report in the manuscript. Our
approach was to compare the serotonin transporter gene (SERT or
SLC6A4). The SLC6A4 gene belongs to the same family of
monoamine transporters and exhibits a high degree of sequence
similarity with the SLC6A3 (BLAST E-value=2
e-166); nevertheless,
these genes have strikingly different expression patterns suggesting
differences in their regulation. In addition, we considered that our
comparative analysis would clarify whether the genomic features
of the SLC6A3 gene are truly unique or shared with phylogenet-
ically related genes.
We first scrutinized in detail the gene sequences to identify
various genomic characteristics may factor into expressional
diversity. Next, we looked at different arms of gene regulatory
network individually to identify which are involved in the SLC6A3
regulation (Figure 2). Subsequently, we assessed a potential impact
of the individual variations in the gene sequence on the gene’s
sensitivity to a particular regulatory mode and on its downstream
phenotypic manifestations.
Our findings reported here deepen current understanding of the
functional significance of the variations in the DAT1 sequence. We
provide evidence that the individual variations on a sequence level
ultimately affect DAT’s epigenetic sensitivity and the interplay of
genetics and epigenetic mechanisms gives rise to wide diversity of
dopaminergic phenotype. We identified new genetic targets;
should experimental testing validate their biological significance,
these targets potentially will have practical implication in
advancing the development of treatment strategies and improving
reliability of genetic screening of devastating diseases arising from
impairments of the dopaminergic circuits.
Results
Conserved elements in the genetic loci
The protein composition of dopamine transporter is highly
evolutionally conserved reflecting the fact that dopaminergic
neurotransmission is an ancient signaling mechanism. However,
conservation on the protein level is not reciprocal with
conservation on the genome level. As is evident from the
Figure 3A, sequence conservation of the SLC6A3 locus across
phylogenies at most is very limited: Sparse conserved elements are
confined to coding sequences whilst the regulatory regions,
including promoter, introns and 39-UTR do not exhibit
conservation (Vertebrate Multiz Alignment and Conservation,
44 species). Far more pronounced conservation is apparent in the
SLC6A4 locus with major conservation spikes corresponding to the
coding regions, 59 regulatory region and 39-UTR (Figure 3B),
suggesting that the other genes of monoamine transporter family
are much more conserved. Phylogenetic analysis using other
programs produced similar results, thus, our inspection of the
entire SLC6A3 and the SLC6A4 loci (ORKA toolkit, PhastCons
multi-species analysis) revealed only 3 conserved regions in the
SLC6A3 locus (including 5 kb flanks) versus 13 regions in the
SLC6A4. Since evolutionary conservation commonly serves as a
metric for identifying putative regulatory regions, the results of our
analyses indicate that the regulatory mechanisms controlling the
human SLC6A3 evolved recently. Strikingly, even core promoter of
the human SLC6A3 (Figure 4 A) displays similarity with primate
but not with other mammals where low complexity repeat (green)
occur only in human genome. The SLC6A4 core promoter is far
more phylogenetically conserved (Figure 4 B, blue dotted box).
Extended promoter region of the human SLC6A3 is unique
(Figure 4 A, blue arrow), while the sequences of extended
promoter of the SLC6A4 are similar in human and chimp
(Figure 4 B).
The poor conservation of the DAT1 locus might signify that the
abundant changes in the sequence all are ‘‘effectively neutral’’,
that is, they do not affect fitness [22]. However, this is not the case
because we noticed that the surrounding chromosomal regions do
not exhibit such conservation dips. Accordingly, the changes in the
SLC6A3 sequence are rather locus-specific and can not be
explained by isochore structure of the chromosomal region thus
suggesting that the other evolutional forces drive this process, a
bias gene conversion [23] for example. On the evolutional
timescale, it appears that the major changes on the DAT sequence
occur after a chromosomal translocation event during which the
SLC6A3 locus changed its genomic position from chromosome13
in rodents to chromosome5 in primates. Expectedly, the loss of the
synteny of the genomic locus, which entails a very dissimilar
chromosomal environment, adds to the phylogenetic divergence of
the regulatory mechanisms of the SLC6A3.
Reconstruction of hominid evolutionary history revealed that
the ancestral branch leading to primates and humans experienced
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whereas the rate of other types of genomic rearrangements, such
as single-base-pair mutations, was far slower [24]. The SLC6A3
locus is characterized by abundance of repeats and occurrence of
chromosomal rearrangements (see below). Moreover, much of
repeat polymorphisms in the DAT1 sequence, including 39UTR
VNTR, is specific for human lineage and not shared even with
primates, suggesting that these variations are positively selected.
Interestingly, it is postulated that the sequences that are not shared
between human and chimps may be important for human-specific
traits [25].
Sequence Variations
Much recent progress defining the molecular basis of pheno-
typic variability resulted from studying genomic DNA. Since this
topic is extremely broad, in this analysis we focus on three major
types of sequence variations, that is, single nucleotide polymor-
phisms, repeats and large-scale copy number variations. The
Table 1. Databases and Computational tools used for the analysis.
Functional modules Genomic features Toolkit
Sequence variations SNPs Genome Variation Server - http://gvs-p.gs.washington.edu/GVS
NCBI dbSNP - http://www.ncbi.nlm.nih.gov/projects/SNP,
Tandem repeats UCSC Browser tools - http://www.genome.ucsc.edu
Tandem Repeat Finder - http://tandem.bu.edu/trf/
SERV - http://www.igs.cnrs-mrs.fr/SERV/
Mobile portal, e-tandem and geecee - http://mobyle.pasteur.fr/
TandemSWAN - http://favorov.imb.ac.ru/swan/
Copy number variations Database of Genomic Variants - http://projects.tcag.ca/variation/
Clusters of short interspersed repeats REPFIND - http://zlab.bu.edu/repfind/
Cis-and Trans-Regulatory
regions
Promoter prediction Promoter 2.0 - http://www.cbs.dtu.dk/services/Promoter/
Eponine TSS - http://www.sanger.ac.uk/Users/td2/eponine/
CoreBoost_HM - http://rulai.cshl.edu/tools/CoreBoost_HM/
Alternative promoter PROSCAN - http://www-bimas.cit.nih.gov/molbio/proscan/
PAZAR database - http://www.pazar.info/, ORCA toolkit
Transcription Factor Binding
Sites
CisRed - www.cisred.org/;
JASPER - http://jaspar.cgb.ki.se/.
Cluster-Buster - http://zlab.bu.edu/cluster-buster/.
Sequence features QGRS Mapper - http://bioinformatics.ramapo.edu/QGRS/analyze.php
Nucleosome positioning NXregions - UCSC Browser, Custom Track
mRNA processing and stability Alternative splicing SPLICY - http://host10.bioinfo3.ifom-ieo-campus.it/splicy/
EBI ASTD - http://www.ebi.ac.uk/astd/main.html
ExonScan - http://genes.mit.edu/
SpliceInfo - http://140.113.239.236/SpliceInfo
39-UTR secondary structure GeneBee - http://darwin.nmsu.edu/,molb470/fall2003/Projects/samara/genebee.html
SECentral Clone Manager Suite
microRNA mirBASE - http://microrna.sanger.ac.uk/sequences
TargetScan - http://www.targetscan.org/
Pictar - http://pictar.mdc-berlin.de/
EBI ASTD - http://www.ebi.ac.uk/astd/main.html
doi:10.1371/journal.pone.0011067.t001
Figure 2. Gene expression regulatory mechanisms: schematic overview. Gene expression represents a multistep pathway that involves
highly regulated and interconnected events; conceptually, it could be divided on transcription, mRNA processing and RNA turnover. Transcription
rate is settled on genetic and epigenetic features of gene sequence; differential mRNA processing includes alternative splicing of transcripts, and RNA
turnover rate which is determined by RNA stability depends on the RNA interference and nonsense mediated decay (NMD).
doi:10.1371/journal.pone.0011067.g002
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increases the spectrum of potential genetic variability, both
enhancing the complexity of ‘normal’ genome and highlighting
these forms of genetic variation as potential disease mechanisms.
Simple Nucleotide Polymorphisms (SNPs). Point muta-
tions in the DNA sequence (SNPs) are considered as major source
of genome variations and are the best understood mechanism for
phenotypic change [26]. Traditionally, genetic studies addressing
such polymorphisms focused only on non-synonymous coding
SNPs assuming that only these are functionally significant.
Recently, it became apparent that so-called synonymous
mutations are not neutral [27] but affect gene expression in
several different ways. For example, SNPs occurring in 39-UTR
SNPs modulate the translation process by impacting mRNA
transport [28], interference with the compartmentalized
expression of tissue-specific genes in particular cellular loci [29]
and altering mRNA stability [30]. Non-coding SNPs may trigger
nonsense-mediated decay [31], inactivate the native splicing site
[32], hinder posttranslational mRNA modifications [33].
Synonymous SNPs, while not affecting amino-acid composition
of the cognate protein, may lessen accuracy and reduce translation
rate [34], thereby leading to aberrant protein folding [35] because
all these processes rest upon codon specificity.
Multiple SNPs are mapped to the SLC6A3 locus: The NCBI SNP
database (frozen April 7, 2009) lists 897 of them. This number
significantly exceeds the number of SNPs in the other genes of the
monoamine transporters family; thus the SLC6A4 gene has 441 SNPs
and the SLC6A2 (norepinephrine transporter gene) has 514 SNPs
(Figure 5A). Not only the numbers, but also the patterns of the SNPs
distribution in the SLC6A3 and in the SLC6A4 loci are markedly
distinclt: SNPs are found in virtually all SLC6A3 domains (flanking
regions, coding sequences, exons and introns), whereas in the
SLC6A4, they largely are confined to the UTR region (Figure 5B).
The thirty-three SNPs mapped to the SLC6A3 39-UTR
potentially can hinder localized translation of the DAT1.W e
noted (GVS) that the 39UTR SNPs have low conservation scores
(mostly 0.000), indicating an evolutionally recent origin, so they
likely are human-specific. Considering that five 39UTR SNPs are
common in human populations, with minor allele frequencies of
16% and higher (Table S1 lists the SNPs), they might add a factor
to the variation in DAT1 expressional. Interestingly, two SNPs in
the SLC6A4 39UTR have high conservation score (0.99 and 0.98),
suggesting that they occur in different species.
The 59 gene region is pivotal for regulation, it encompasses
binding sites for transcription factors and components of basic
transcriptional machinery; consequently, it is unsurprising that
59UTR often is highly conserved and rarely carries variations. We
found that the 59 regions of the SLC6A3 and the SLC6A4 genes
have 31 and 12 SNPs, respectively, suggesting that they might
confer expressional variability.
Below, we elaborate on possible functional consequences of
SNPs in regards to their potential impact on particular regulatory
mechanisms.
DNA repeats. Repeated DNA sequences are common
feature of the human genome (209,214 loci, according to [36]).
Organized in tandem DNA repeats (tandem repeats) are
inherently unstable, and known to be the ‘‘hotspots’’ for
mutations [37]. However, their abundance in the human
genome posits that they may not be strictly deleterious but
might confer some evolutionary advantage, such as affording
transcriptional divergence, for example [38].
The 39 UTR VNTR of the SLC6A3 is the most studied
polymorphism in this gene and has been linked to variety of
clinical conditions [39]. The VNTR in the intron8 of the DAT1
was also explored in clinical- and preclinical settings and was
linked to cocaine abuse [40] and smoking cessation [41]. The high
SNPs frequency in the SLC6A3 gene led us search for possible
repeat variations in its sequence. We analyzed the current version
of the SLC6A3 sequence (Human 2009 Assembly (hg19) running
several ab initio prediction programs. We repeated the same
Figure 3. Conservation profiles of the SLC6A3 and the SLC6A4 genomic regions. Conservation tracks of the cognate genes loci shown in
UCSC Genome Browser interface. A new Conservation track includes a 44-way vertebrate alignment; the subtracks display phyloP scores (in blue and
red). Red arrow points to the promoter regions. The 39-end of the genes framed in the green box. Note that the conservation of the regulatory
regions across vertebrate species is evident only in the SLC6A4 locus. In contrast, in the SLC6A3 locus the only visibly prominent is the ‘‘negative’’
phyloP track, which score indicates accelerated evolution of the region.
doi:10.1371/journal.pone.0011067.g003
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outputs were different in actual numbers of the repeats, the results
were consistent. The Tandem Repeats Finder (TRF 4.04) [42]
that uses conservative approach, detected 71 repeats, the e-tandem
identified 30 regions and the TandemSWAN [43], designed to
identify imperfect or ‘‘fuzzy’’ repeats generated more than 600
hits.
Intrigued by the high number of repeats, we wanted to define
some principal parameters associated with tandem repeat
polymorphism in order to predict their variability (or hypervaria-
bility). G + C content of the sequence is a strong predictor of
minisatellite polymorphisms [44], and, since the SLC6A3 sequence
composition is CG bias (0.55, geecee of Mobyle Portal) it is likely
that at least some of newly predicted repeats are polymorphic. The
SERV software [45] assessed the polymorphic potential of the
predicted repeats by assigning the score to the repeat region
(VARscore). The score value between 1 and 3 was proposed as an
indicator of potentially good genotyping target, and it was found
that the VARscore and experimentally determined polymorphisms
are in good correlation [45]. Seven of the SLC6A3 repeats had the
optimal score thus representing potential new genotyping targets
(Table S2). We noted that the VARscore 2.31 was assigned to the
39UTR VNTR region; this fact strengthens the validity of our
computation. It is noteworthy that the sequences of the longer
tandem repeats in the SLC6A3 locus often itself contain simple
repeats. Simple repeats, especially trinucleotide repeats such as
CAG, CTG, CGG, are the most unstable and often are associated
with human diseases.
We used the same methodology to analyze the SLC6A4 gene: in
this sequence the SERV detected 40 repeats, the Mobile portal
found 11 and the TRF found 30 repeats. In contrast to the
SLC6A3, the repeats in the SLC6A4 have shorter consensuses
Figure 4. Conservation blocks in the 59 regulatory regions of the SLC6A3 and the SLC6A4 genes. The ECR Browser was used to identify
conserved regions within the cis-regulatory sequences of the SLC6A3 and the SLC6A4 genes. In the SLC6A3 (panel A) sequence similarity of core
promoter is limited to the Pan troglodyte; a low complexity repeat (indicated by green arrow) that resides in the core promoter of the human gene,
lacks in the primate gene. The sequence of extended promoter presumably containing promoter enhancer elements (shown in red) is uniquely
human as well (blue arrow). Core promoter of the SLC6A4 is phylogenetically conserved across multiple species (panel B, blue box); its extended
promoter is shared between humans and primates.
doi:10.1371/journal.pone.0011067.g004
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(Table S3). For the potentially novel genotyping targets, we might
consider only one region (VARscore 1.36). Of notice, analyses
were limited to the gene sequences; therefore the region of the 5-
HTTLPR polymorphism was outside the scope.
Copy number variations (CNVs). Copy number variations
refer to the incidence of additional or missing chromosomal
segments in some individuals, adding another dimension of
variation to the genome [46]. This genomic feature is highly
prevalent: about 13% of human genes overlap with CNVs [47].
CNVs are significantly overrepresented in telomere-proximal
regions and in simple tandem repeat sequences; they often
detected in genes that have significantly elevated nucleotide
substitution rates. The non-uniform distribution of CNVs in the
human genome suggests that they have functional consequences;
according to Fraser and others, [48], CNV’s contribution to
genetic diversity might exceed the combined contributions of all
other genetic variations. As thought, the CNVs might help to
explain some cases of diseases with evident genetic causation but
lack of a genetic clarification [49].
Multiple segmental duplication in human genome are recent
and a large fraction of these regions is not duplicated in the
chimpanzee (Pan troglodytes) genome [50]. Of direct relevance to
the subject of our analysis is the fact that the localization of these
human-specific duplications is bias for chromosomes 5 and 15
[51].
Our inspection of the SLC6A3 locus (DGV) revealed three
structural variants mapped within the gene body (Figure S 1. Note
that the largest CNV (36355) involves two exons – exon 5 and
exon 6). However, that the actual number of the CNVs in the
Figure 5. SNPs frequency and distribution within the chromosomal regions of the SLC6A3 and the SLC6A4 genes.A–Chromosomal
maps were produced by the Genome Variation Server in a ‘‘summary SNPs display’’ view (the SLC6A3 map - top panel, and the SLC6A4 map – the
lower panel). Single peaks are indicating genomic positions of SNPs where peaks height corresponds to the SNP frequency (filtering – default options,
merge option - common samples with combined variations). B-Regional frequency of the SNPs in the SLC6A3 (left) and the SLC6A4 (right).
doi:10.1371/journal.pone.0011067.g005
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the latest release of Human Genome Assembly (hg19, 2009,
UCSC) include references to the multiple deletions of different
sizes, including a deletion of 489 nucleotides (dbSNP build 130
rs71309291). Considering that CNVs data are obtained by
analyzing genomic DNA from healthy individuals [46], the CNVs
detected in the DAT1 sequence have no apparent phenotypic
consequences or have only subtle effects. Alternatively, these
findings might be limited to a particular subpopulation of the
blood cells (mosaicism) that arise due to the inherent genomic
instability of the SLC6A3 locus. The high rate of the CNV
occurrence in the DAT1 locus (three out of eight individual
genomes tested revealed CNVs in the DAT1 gene), indicates that
the copy number variations encompassing the DAT1 locus are
frequent in the normal population and, therefore, may be
advantageous. Lack of CNVs in the SLC6A4 and the SLC6A2
loci suggests that, in contrast to the SLC6A3, they are controlled by
purifying selection.
Transcriptional regulation
Inspection of the Promoter region. Our next step was to
explore the promoter region of the SLC6A3. Experimental and
clinical evidence indicates that sequence variations upstream of the
transcription start site (TSS) affect DAT1 transcriptional regulation
[52]; therefore, we evaluated the promoter region in greater
details. A promoter sequence represents a template recognized by
the transcriptional machinery; therefore promoter analysis is
essential for understanding transcriptional regulation of the
cognate gene. It is difficult to accurate locate the position of
the TSS and to exactly specify the promoter region because the
sequences of the human promoters have exceedingly diverse
characteristics.
Since the SLC6A3 core promoter lacks ‘‘TATA’’ and ‘‘CAT’’
boxes (these DNA sequences provide docking sites for basal
transcriptional complex) [53], we must identify other regulatory
sequence elements that could substituting for them. Transcrip-
tional initiation of neuronal genes often is facilitated via binding of
core transcriptional machinery to the CCAAT element [54]; not
unexpectedly, we detected several CCAAT consensuses upstream
and downstream of the SLC6A3 TSS suggesting that the SLC6A3
might be one of these. Human genes that have CCAAT-promoters
display several common characteristics; in general, they are less
precise in terms of TSS then the genes with TATA-promoters and
they mostly overlap with CpG islands. Transcription initiation
from the CCAAT box involves NF-Y, an element with histone-like
features, and a particular subset of transcription factors [55]. Both
features are relevant to the epigenetic sensitivity of the SLC6A3 as
we elaborate later.
Comparing the regulatory regions of the SLC6A3 and the
SLC6A4 revealed their markedly different regulatory potential.
While regulatory region of the SLC6A4 displays characteristics of a
strong promoter (high significance of predicted TSS), the 59 region
of the SLC6A3 does not display the typical sequence characteristics
of a strong promoter. Here, de novo predicted TSSs are only
marginal (Promoter 2.0 Prediction server) or off-target (Softberry).
The software Eponine (Sanger) predicts multiple low-score
(ambiquious) TSS sites are predicted by the Eponine, the
CorePromoter [56] denotes ten putative TSSs with comparable
low scores and the AceView [57] predicts three putative
alternative promoters for the SLC6A3 gene.
The complex structure of human gene promoters with a range
of alternative transcription start sites (TSSs) [58] supports
differential temporal- and spatial- patterns of gene expression
and provide an additional level of gene regulation by modulating
translational efficiency [59]. About one fifth of human genes have
alternative promoters; this phenomena is most frequent in brain-
related genes [60]. Based on our analysis we might categorize the
SLC6A3 promoter as a broad one; in addition, absence of a strong
promoter indicates the potential for off-target transcription
initiation.
The heterogeneous dopaminergic neurons within the mesocor-
ticolimbic dopamine system have distinct anatomical and
physiological properties [61], therefore, the biological identity of
a specific subpopulation of dopaminergic neurons might be
enabled by preferential transcription of particular mRNA. Our
computational prediction that the SLC6A3 transcription might
lead to production of different mRNA isoforms is strengthened by
in vivo-derived evidence: the SLC6A3 transcripts of different length
were detected in different brain regions (long transcript M95167 in
the brain stem [62], and short transcript, L24178, in Substantia
Nigra [63]), suggesting that alternative transcription initiation
might enable region-specific expression of the SLC6A3. Further-
more, differential transcription initiation might be a means for a
rapid switch in response to the acute environmental cues:
Prefolded RNA structures are less efficient in adopting environ-
mental changes into expressional changes [64,65], which might be
explained as reflecting the high thermodynamic barriers to
interconversion between the secondary structure isoforms.
Whether the SLC6A4 regulation involves similar regulatory
mode remains unclear since almost all RefSeq annotated human
SLC6A4 transcripts are of somatic origin (placenta, lung) and of
similar length. However, it is likely that it, indeed, utilizes AS,
given that the rat Sert gene has two alternative promoters and its
transcripts are alternatively spliced in a tissue-specific manner
[66].
Transcription factor binding sites (TFBSs). The
interaction of the cis-regulatory elements of a gene with
transcription factors (TF) largely determined transcription event,
therefore, an assessment of the putative TF binding sites in the
regulatory region of the gene under analysis yields important
information on this gene’s regulation. In the nervous system, TFs
define the basic framework [67]; their availability varies across the
brain regions and cell types thus contributing to the phenotypic
diversity [67];. As we mentioned, the nature of the SLC6A3
promoter (CCAAT promoter) implies its sensitivity to selective
TFs, because NF-Y synergistically interacts with a subset of TFs
[55]. Our inspection of the SLC6A3 59-flanking sequence (22 kb,
JASPAR database) revealed that it contains binding sites for Sp1,
GATA-1, CREB, and c-Myc cis-acting regulatory elements –all
those TFs interact with NF-Y [55]. The Sp1-sensitivity of the DAT
transcription was previously demonstrated in vitro [68], thus
validating the biological significance of the sites we detected.
Sp1 is a key element of non-classical genomic nuclear receptor
pathways mediating hormone-dependent gene activation and
repression suggesting the possibility of the involvement of a
hormonal element in DAT regulation.
The nucleotide sequences recognized by individual TFs are too
small and degenerate to enable detection of functional enhancer
and silencer elements within the genomic context. Therefore, it
was postulated that dense clustering of the motifs may improve the
accuracy of their recognition and enable better control of the gene
expression level [69]. Using the Cluster-Buster web server [69] to
query promoter sequences of the SLC6A3 and SLC6A4 genes, we
found a high-scoring (9.15) cluster in the SLC6A4 but not in the
SLC6A3. Next, we compared the TFs profiles of both genes
(CisRED [70]) noting their distinctions (Figure S2). While the
lengths of the cisRED regions are comparable, they differ in their
architecture: The atomic TF motifs are densely clustered in the
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SLC6A3 regulatory region. Collectively, these results suggest that
TFs-mediated transcription more important for the SLC6A4
regulation than for that of the SLC6A3.
Quadruplex forming G-rich sequences in pre-mRNAs and
mRNAs (QGRS). The unusually frequent occurrence of CG
nucleotides in the SLC6A3 sequence (CG content 0.55 compare to
0.47 in the SLC6A4 sequence) likely influences the physical
properties of the DNA molecule, since guanine-rich DNA tends to
adopt a four-stranded structural form known as a G-quadruplex,
or G4 DNA [71]. QGRS are highly conservative and often found
in key chromosomal regions, suggesting that they have functional
significance. When located in the promoter region, G-quadruplex
structures can act as cis-regulatory elements and either enhance
transcription of, or silence the respective gene. Apparently, natural
selection progressively favored the canonical G4 DNA motifs
within regulatory regions and, consequently, G4-formation has
been proposed as a mechanism for regulation of gene expression in
eukaryotes [71]. CG-rich mRNAs also form highly stable G-
quadruplex structures [72], which play major role in mRNA
turnover [73] and translation [74].
To gain an insight on the involvement of G4 DNA formations
in the regulation of the SLC6A3, we analyzed the landscape of G4
DNA (PG4Ms) motifs in the human SLC6A3 gene using the GRS
database [73] with the default settings and filters of the server.
Unexpectedly, we found that the multiple G4 motifs that are not
restricted to the TSS-proximal regions. The number of non-
overlapping QGRS in the SLC6A3 sequence (474) almost doubles
the number of G4s in the SLC6A4 and the SLC6A2 sequences (203
and 281, respectively). This high score of detected QGRSs
increases the likelihood that G-quadruplex structures form in vivo,
thus, adding another factor to the SLC6A3 regulation. Importantly,
several QGRS were detected in the vicinity of the intron-exon
junctions of the SLC6A3: Because G-rich quadruplexes are actively
involved in alternative and tissue-specific regulated splicing events
[75], their positional effect on gene expression and the implication
for DAT function could be most profound.
Post-transcriptional regulation
Post-transcriptional level of gene regulation comprises a series of
post-transcriptional and -translational mechanisms that increases
the complement of neuronal transcripts and protein isoforms [76].
Neuronal mRNAs are diversified through several processes
including alternative splicing, compartmentalized translation,
and RNA editing. In most tissues, transcription-generated RNA
base sequences experience downstream alterations; this ubiquitous
process is particularly active in the nervous system [77].
Short interspersed repeats. One of the mechanisms of
gene regulation involves controlled transport of the mRNA to the
subcellular compartment where the gene’s protein products are
used. The half-life of a particular mRNA depends in part on the
sequence of the 39 UTR of the transcript such as clusters of short
interspersed repeats (4–7 bp) that can regulate alternative splicing
and mRNA stability [78]. We identified more that fifty short
repeated units in the 39- UTR of the SLC6A3 (about 2 kb)
(REPFIND [79]) with a P-value less than 1.11
e-16, signifying that
they are not random but likely to be of functional significance
(Figure S 3A). A similar analysis of 39-UTR of the SLC6A4
revealed only ten short repeated units, with weaker significance
where the smallest of P- values, assigned to one of the repeats, was
7.78
e-06. We noted that short interspersed repeats are scattered
across the 39 region of the SLC6A4, whereas in the SLC6A3 gene,
they are largely confined to the middle of the 39-UTR. This is an
important fact, since this positional overlap suggests that the length
of the polymorphism directly affects the number of the short
interspersed repeats.
In neurons, effective mRNA translation occurs near dendritic
terminals [80,81]. The binding of specific proteins to cognate
mRNA sequences and formation of translocationally-competent
nucleoprotein complexes enables the intracellular trafficking of
mRNA molecules. The proteins of translocation machinery
recognize CAG or CAG-containing repeated motifs in the 39-
UTRs of the mRNA molecule; such short motifs are commonly
detected in genes that are translated in dendrites [79,82].
Assuming that the SLC6A3 is one of such genes, and its translation
likely occurs near synaptic terminals, we screened its 39 UTR for
CAG motifs; as expected, we found multiple such tri-nucleotides
repeats and repeats clusters (Figure S3B). Surprisingly, we did not
detect CAG motifs in the 39 UTR of the SLC6A4. The basis for
this difference is unclear, since in applying the same reasoning,
SLC6A4 translation in neurons is likely to take place near synaptic
terminals. Possibly, the lack of a translocation signal is due to the
abundant expression of the SLC6A4 in non-neuronal cells.
Alternatively, the intracellular translocation machinery might
recognize the sites within the coding sequence of the SLC6A4
mRNAs, as was established for the dendritic trafficking of the
BDNF transcripts [83]. Notably, the short interspersed repeats and
the 39-UTR VNTR polymorphism of the SLC6A3 reside in the
same region, suggesting the complexity of possible biological
effects of sequence variations occurring therein. We will discuss
this issue in more detail later.
Splicing and Alternative splicing. Because pre-messenger
RNA of contain multiple introns, the splicing is a critical step in its
expression. Alternative splicing (AS) generates multiple splicing
isoforms with different combination of exons thus dramatically
increasing the molecular complexity of the expressed proteins [84].
The AS rate progressively increased during evolution: in yeast only
a small portion of genes is alternatively spliced, while in the human
genome, the majority of protein-coding genes are known to
undergo alternative splicing [85,86], [87]. The production of
differential isoform varies across tissues and cells: the rate of AS
events and the level of alternatively spliced mRNA in the brain are
much higher than in somatic tissues [88,89].
We searched for evidence supporting the involvement of AS in
the SLC6A3 regulation. Both, the SLC6A3 and the SLC6A4 genes
have 15 exons, viz., more than the average of 9 exons for a human
gene; and genes with higher number of introns and exons more
often utilize AS. We also found a) there are at least three different
mRNAs transcribed from this locus (AceView); b) the SLC6A3-
mRNA L241781 encodes 11 exons (exon skipping, SliceInfo); and,
c) two plausible intron/exon structures for the SLC6A3 mRNA
containing 15 and 16 exons (SPLICY database) as evident from
microarray experiment data (probeset annotations). In addition,
an ambiguity in position mapping for the first exon of the SLC6A3
(First EF) and the number of ab initio predicted exons (26, as by the
ExonScan) corroborate the possibility of AS of the SLC6A3
transcripts.
The splicing pattern might be dynamically regulated by external
stimuli; in fact, most cellular signaling pathways that change gene
transcription also alter groups of alternative exons [90]. Neuronal
activity and drugs can induce alternative pre-mRNA splicing
[77,91,92]. For example, cocaine and dopamine trigger the
synthesis of the ania-6 (cyclins protein family) in the brain,
whereby, depending on the nature of the stimulus, AS generates
two distinct ania-6 mRNAs that then are translated to functionally
different proteins [93].
Fox-1 and Fox-2 proteins were identified as regulators of the
neuron-specific splicing pattern [94] [95]. They contain a single
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enhancer in the intron downstream from many exons, and might
induce exon skipping [95]. Fox proteins mediate splicing of many
genes critical for neuronal development and brain function [96].
We found multiple high-scoring binding sites for Fox2 family
proteins on the SLC6A3 and SLC6A4 transcripts suggesting they
may represent an AS regulatory element.
Splicing machinery recognizes flanking sequences around the
exon-intron junctions (,20 bp); they are pivotal for the fidelity of
the splicing process. Mutations within the splice sites of their
auxiliary elements can either affect the splice site’s efficiency
abolishing splicing or alter the balance of the alternatively spliced
forms, so modulating the phenotypes of the cognate gene’s
[97,98]. The functional consequences of SNPs in the exon-intron
junctions are as profound as those for SNPs in the coding regions
[99,100]. Splicing errors are implicated in pathogenesis of various
diseases, including neurological diseases and malfunctions [101].
Strict selection control of exonic splicing elements explains the
rarity of SNPs near intron-exon boundaries [102]. Contrary to our
expectation, we found twenty- five DAT’’s SNPs and eleven
SERT’s SNPs in the exon-intron junctions (Galaxy Browser).
Apparently, these SNPs increase a probability of splicing errors,
thereby engendering aberrant transcripts.
MicroRNA (miRNA). A miRNA-mediated mechanism that
destabilizes transcripts regulates gene expression at the level of
translation (reviewed in [103]). MiRNAs play a primary role in
controlling gene expression during development but also in post-
mitotic cells, such as neurons, and apparently contribute to age-
dependent variation in gene expression [104,105]. While
repressing target genes in actively proliferating cells, MiRNAs
can activate gene expression in non-dividing cells such as neurons
[106]. The sites of miRNA recognition often are found in the
39UTR region [107]. To retrieve information on miRNA binding
sites for the SLC6A3 and the SLC6A4 sequences we used the
MirBase Target Database software (Welcome Trust), which
recognizes 14 and 57 targets, while EBI ASTD, recognizes 107
and 46 targets, respectively. The identification of multiple targets
supports the possible involvement of the miRNA machinery in
regulating both genes.
Recently, our understanding of the mechanisms of miRNA-
mediated gene regulation was broadened due to the discovery that
human-specific miRNAs interact with sites in the 59-UTR motifs
[108]. An important sophisticated facet of this work was the
finding that the miRNAs of this novel class interact simultaneously
with both 39 and 59 UTRs targets; this ‘‘double’’ targeting greatly
enhances miRNA’s ability to down-regulate the gene expression.
We found that the SLC6A3 and the SLC6A4 -genes are amongst
the targets for this novel class of miRNAs (miBridge, [108]). In
particular, the SLC6A3 UTRs contain consensus sequences
recognizable by eight miBridge’ miRNAs, while the SLC6A4
UTRs contain consensuses for 4 miRNA of this class. The target
prediction algorithm implemented in the miBridge is more
stringent than those in other software, and consequently, the
number of genes predicted as miRNA targets by miBridge is low;
however, the multiple identification of the SLC6A3 gene as a target
underscores the importance of miRNA-mediated control in its
regulation.
Differences in conformational structure of SLC6A3
transcripts and their stability offer a putative mechanism
explaining biological significance of the 39VNTR
polymorphism. The half-life of a particular mRNA depends
in part on the sequence of the 39 UTR that can regulate
alternative splicing, the intrinsic stability of a cognate mRNA and
its sensitivity to regulation by miRNA [78]. Transcript length,
however, also determines the RNA’s secondary structure; hence,
various SLC6A3 transcripts might fold differently. The
conformation of the RNA molecule is essential for its biological
function; it determines the translational rate and the biological
catalysis of a transcript [109,110]. We determined that the length
of the SLC6A3 mRNAs correlates with the stability of their
compacted structures (results in Table 2), suggesting that there is
yet another regulatory mechanism for the DAT gene that might
operate via preferential transcription of one mRNA over another.
More specifically, cells might employ a rapid switch in
transcriptional mode to achieve fast increase in DAT level,
hence, rapid synthesis of DAT protein; whereas the production of
longer, more stable transcripts prolongs translation time
determining basal DAT’s level.
The 39UTR VNTR polymorphism of the SLC6A3 apparently
changes the transcript length; therefore we sought that these
differences might be a factor contributing to the phenotypic
differences ascribed to the particular alleles. Following the original
discovery of this polymorphism [111], there have been many
experimentally and clinical investigations. The finding that the
number of the tandem repeats affects the transcriptional efficacy of
the DAT was confirmed by different experimental means but failed
to provide satisfactory explanation to tshe phenotypic differences
observed in vivo. By definition, 39UTR variation does not affect the
protein product; hence, it ought to exert its influence on the level
of transcripts. We hypothesized that the actual number of the
repeated consensuses in the cognate allele would determine the
secondary structure of the corresponding SLC6A3 transcript. We
tested our hypothesis by modeling the secondary structures of
putative mRNAs containing 9 versus 10 repeats, which correspond
to the most common alleles in the population (GeneBee server
[112]. We found a notable difference in the free energy of the
predicted secondary structures of the respective mRNAs, viz.,
2135 kcal per mol (10 repeats), versus 295 kcal per mol (9
repeats) (Figure S4A). Further, we noted that the folding structures
of mRNAs i.e., the tendency towards hairpin formation also are
subordinate to the repeats number: Duplexes formed by the 9-
repeat sequences had longer stems and higher energy than those
formed by the 10-repeat sequences (214.4 kcals versus 7.4 kcals)
(SECentral Clone Manager Suite 7 program) (Figure S 4B). In
sum, our analyses revealed that the number of the 39 UTR repeats
might affect the SLC6A3 expression in several different ways;
specifically, by transforming the secondary structure of the cognate
transcript and modulating its propensity to form hairpin
structures. The conformational differences of the mRNAs
Table 2. The length of the SLC6A3 mRNAs correlates with the
stability of their compacted structures.
mRNA
mRNA
length
Free Energy
of assembly
Ensemble
Diversity
M95167.1 3946 nt 21716.51 kcal/mol. 792.13
S46955.1 3919 nt 21698.40 kcal/mol. 960.43
BC132977.1 2774 nt 21176.54 kcal/mol. 1032.98.
BC133003.1 2774 nt 21176.54 kcal/mol. 1032.98.
S44626.1 2020 nt 2868.85 kcal/mol. 678.67
L24178.1 2010 nt 2867.45 kcal/mol. 427.14.
Note that increase in the mRNA length correlates with corresponding increase
in free energy of secondary structure. Highest Ensemble diversity is predicted
for the transcript isoforms of a medium length.
doi:10.1371/journal.pone.0011067.t002
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impact on other regulatory mechanisms, including the number of
putative miRNA target sites facing the surface of the molecule
could vary, changing the transcript’s degradation rate. In a similar
fashion, the colocalization of the 39UTR VNTR region with the
region of short interspersed repeats points to their co-regulation.
Epigenetic regulation of the SLC6A3 and the SLC6A4
genes
Several studies have analyzed known polymorphisms in the
DAT and the SERT genes as a function of specific environmental
factors [113] proving that adverse environments entail disordered
behavioral manifestations more often in the carriers of particular
polymorphisms. There is a common agreement that the
environmental factors play a role in the pathogenesis of brain
disorders, but the mechanisms of gene-environment interactions
on molecular level remain poorly understood. Our knowledge on
the epigenetic status and dynamics of epigenetic processes
regulating the SLC6A3 and the SLC6A4 is very limited due to
significant technological challenges; therefore, systematic identifi-
cation of possible targets amenable to epigenetic modifications by
computational means intrinsically is worthwhile. Further, since a
computational analysis is sequence-based, it is not influenced by
the innate variability of experimental conditions.
DNA methylation. DNA methylation in the mammalian
genome predominantly occurs on cytosine in context of the 59-
CpG-39 dinucleotides; this is the only type of epigenetic
modifications to directly change the DNA molecule. Stretches of
GC-rich sequences in the genome called CpG islands (CGIs) that
are associated with open transcriptionally competent chromatin
structure were discovered in gene promoters [114]. The relevance
of GC content and CpG dinucleotide concentration to the
regulation of gene activity points to its physiological significance.
The methylation status of the promoter-overlapping CpG island
plays a central role in the epigenetic control of gene expression
thus, aberrant methylation patterns (hypo- and hyper-methylation)
can engender gene dys-regulation. Conceptually, an alteration in
the pattern of DNA methylation might serve as an efficient
mechanism for genes to adapt functionality in response to a
variable environment and also might compensate for the effects of
a mal-functional polymorphism. The DNA methylation pattern
established during the development and differentiation is
preserved with high fidelity during cell division by DNA
methyltransferases (DNMTs). DNMTs are highly expressed in
developing tissues but their activity declines during differentiation
in all tissues except the brain wherein they are expressed
throughout the lifetime in the brain [115,116]. Dynamic DNMT
activity in the brain is essential for synaptic plasticity and memory
formation [48,117].
Because CpGs act as a mutation hotspot (deamination of
methylated CpGs to TpGs) and the estimated mutation rates at
CpG sites are about 10–50 times higher than other transitional
mutations, CpG dinucleotides are under-represented in mamma-
lian genomes where they occur at one-fifth of their expected
frequency [118]. The human SLC6A3 gene is remarkably GC
dense and has multiple CpG islands: in contrast to most vertebrate
genes that have only a promoter-overlapping CpG island, all gene
regions of the SLC6A3 display characteristics attributed to this
genomic feature. We mapped twenty-seven bona fide CpG islands
[119] to the human SLC6A3 locus (Figure 6). Notably, even the
‘‘conventional’’ promoter-overlapping CpG island of the SLC6A3
is unusual: on average, in active promoters of human genes
cytosine and guanine account for 57% of the nucleotides [120]
GCs represent 79% of the SLC6A3 promoter sequence. The
frequency of the intronic CGIs is approximately four-times lower
than the expected value [121], yet we found 21 such CGIs in the
SLC6A3. The SLC6A4 locus contains six CGIs, which is also above
average but lower than that for SLC6A3 (Figure 6, bottom panel).
CGIs associated with genes underwent gains and losses during
vertebrate evolution [122]. Human genes generally contain more
promoter-associated CGIs and have more pronounced CGI
characteristics [123] than do mouse genes. Seemingly, the number
of CpG islands in the DAT gene dramatically increased during
evolution: The mouse Slc6a3 has no CGIs, the rat’s gene has one
promoter-associated CGI, while the rhesus monkey’s DAT gene
has two CGIs (one in the promoter and one intragenic). It is
tempting to speculate that the increase in the number of CGIs in
the DAT gene could be evolution-driven and reflects the growing
demands dictated by higher brain function in humans.
Chromatin organization, Nucleosomes. In vivo, the DNA
molecule forms a complex with proteins that allows its packaging
into chromatin. Nucleosomes are the structural units of chromatin
represented by histone octamers around which the DNA coils.
The close interaction of the DNA molecule with a nucleosome
core results in a condensed chromatin that is inaccessible to the
transcription machinery; hence, the transcriptional activation of a
gene requires the local transition of compact chromatin domains
into decondensed loops. Nucleosome remodeling and covalent
Figure 6. Bona fide CGIs in the SLC6A3 and the SLC6A4 regions. Visual displays of the bona fide CGIs (CpG islands) are obtained using Custom
Tracks option (UCSC Genome Browser). Here, blue boxes represent predicted CGIs based on combined epigenetic score. Note, that in the SLC6A3
locus (top panel), multiple GCIs are distributed within all gene regions whereas in the SLC6A4 locus (lower panel), CGIs are evidently less numerous.
doi:10.1371/journal.pone.0011067.g006
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regulation that occur via the modulation of the accessibility of the
genomic loci to transcriptional machinery [124]. Dynamic
chromatin- remodeling events largely determine the frequency of
promoter activation, thus, the expression of many genes could be
mapped to chromatin modifiers, rather than to TFs [125].
CG-rich motifs in DNA sequences inherently disfavor nucleo-
somes, and are referred to as ‘‘nucleosome exclusion sequences’’
(NX) [126]. We found that both, the SLC6A3 and the SLC6A4
genes have high NX-scoring sequences near the TSS (Figure 7).
The predicted nucleosome positioning in the SLC6A3 and the
SLC6A4 loci notably differ: Entire SLC6A3 locus comprises of
numerous nucleosome-dysfavouring sequences, while in the
SLC6A4, NX-peaks are sparse (Figure 7, top and bottom panels).
It was suggested that intragenic regions with high NXScores might
function as transcriptional enhancers (Sawsan Khuri, personal
communication); upon this basis, we interpret the low nucleosome
occupancy of intragenic regions of the SL6A3 gene as indicating
that they might bear regulatory potential. Indeed, several
intragenic NXScore peaks within the SLC6A3, including one in
the 39 UTR, have NXScore value about 600, suggesting that the
open chromatin structure in these regions renders them susceptible
to targeting by chromatin modifiers and possibly by other DNA
interacting proteins.
The same computation assigns the NXScore to the promoter
region that can serve as a proxy to the expression rate of a cognate
gene. The NXScore value for the SLC6A4 promoter (623) agrees
well with the average score value for the promoters of the RefSeq
human genes (about 600). Accordingly, the expression of the SERT
is expected to be rather broad. The score predicted for the SLC6A3
promoter (820) is significantly higher than the average, thus
indicating that expression of the SLC6A3 is not constitutive but
contingent upon stimulation.
Histone modifications. DNA In cell nucleus is found in the
form of a nucleoprotein, wherein histones represent the protein
moiety. The N-terminal tail of the core histone proteins (H2A,
H2B, H3 and H4) is a subject to various types of covalent
modification, including methylation, acetylation, phosphorylation,
sumoylation, and ubiquitination. Combinatorial arrangement of
histone modifications determine the local packaging of the DNA,
thereby influencing gene expression [127]. Acetylated histones
mark actively transcribed genes. Enzymes with opposite functions,
Figure 7. Nucleosome exclusion regions. Nucleosome-exclusion regions (NXRegions) are shown for the SLC6A3 (top panel) and the SLC6A4
(lower panel) genes. The figure was prepared by uploading NXScore results as a Custom Track on the UCSC Genome Browser interface where the
snapshots showing the Known Genes track and Custom Track option were taken for the cognate gene’s loci. NXScore peaks in the SLC6A4 are largely
confined to the TSS vicinity (as it is seen in most of the human genes) and the height of the TSS-overlapping peaks is dominant. Distinctly different
pattern of the nucleosomes is predicted for the chromosomal region corresponding to the SLC6A3: here multiple NXScore peaks are densely mapped
to the different regions of the gene body and to the flanks. Notice that the height of the TSS-proximal NXScore peak is comparable with the other
intragenic peaks.
doi:10.1371/journal.pone.0011067.g007
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(HDACs), maintain the highly dynamics of histone acetylation/
deacetylation status. Histone modifications are highly dynamic
and reversible [128]; they are co-regulated with DNA methylation.
For example, DNA methylation depends on the pre-established
histone 3 methylation at lysine 9 [129] and aberrant DNA
methylation occurs when the local pattern of histone modifications
is distorted [130].
In the adult brain, changes in histone acetylation underlay
synaptic plasticity [117]. Some drugs, including drugs of abuse,
influence histone acetylation status; for example, administratered
cocaine causes histone hyperacetylation [131] and, accordingly,
clinical studies suggest that cocaine craving diminishes after
treatment with valproate [132,133,134]. This evidence sheds some
light on the pathogenesis of addiction: Since valproate has HDAC
inhibiting activity, it is plausible that cocaine-mediated disregula-
tion of gene that causes pathology is mitigated by the treatment.
Both direct- and indirect- empirical evidence supports the
involvement of epigenetic mechanisms in the SLC6A3 regulation:
Thus, it was established that valproic acid, acting via the Sp1 (see
above), up-regulates the SLC6A3 expression in a dose- and time-
dependent manner [135]. In addition, researches using the ADHD
animal model [136] reported that valproate attenuated hyperac-
tive behaviors caused by the incomplete knockout of the Slc6a3
gene. The fact that the SLC6A3 is TATA-less (discussed above)
must also be considered since TATA-less genes, generally, are
biased towards regulation by HAT activity [125].
The collaborative efforts of many research groups have made
experimental data on histone modification available via public
domains. The high-throughput technologies, used to facilitate such
analyses are very powerful yet suffer from limitations including the
potential for inaccurately interpreting the biological significance of
the data. Using cell lines as model systems implies that the
culturing conditions affect their proliferation rate, transcriptional
events and differentiation state. Apparently, the histone modifica-
tion patterns that were detected in actively dividing cells could be
partially related to malignant transformation hence, they can not
be generalized to predict chromatin status in vivo, especially when
considering terminally differentiated post-mitotic cells such as
neurons. However, this information may offer some basic
guidelines. We retrieved a compendium of the available
information via the UCSC Browser (Figure S 5). Histone
modifications mapped to the SLC6A4 locus corroborate well with
the anticipated pattern (Figure S 5B): The TSS proximal region
(+/2 2 kb) displays a characteristic combination of positive- and
negative- histone marks. The SLC6A3 promoter is strikingly
different (Figure S 5A); here, the positive histone marks merely are
present. It is possible that open chromatin conformation in 59 to
the SLC6A4 TSS reflects its broader expression pattern whilst the
lack of acetylated and tri-methylated histones in vicinity of the
SLC6A3 TSS suggests that the experimental cell lines do not
express DAT.
Role of epigenetic mechanisms in transcription
initiation. Histone modifications of the promoter region
reflect the transcriptional state of genomic region, therefore the
human core-promoter prediction software CoreBoost_HM
integrates data on histone modification profiles with important
sequence features. CoreBoost_HM is based on two classifiers, one
for CpG related promoters and the other for non-CpG related
promoters. We applied both classifiers to analyze the SLC6A3 and
SLC6A4 so, to ascertain whether the epigenetic state of the
regulatory region is critical for their transcription (Figure S 6A, B).
As evident from the Figure, DNA methylation does not contributes
equally to regulation of these genes. The SLC6A3 promoter was
detectable only when analyzed as CpG-dependent, while a set up
for CpG island-independent promoter produced no results. In
contrast, for the SLC6A4, both analyses detected a putative
promoter in the region corresponding to the actual TSS.
Discussion
The strikingly polymorphic DAT phenotype in humans and the
biological mechanisms that connect individual genetic back-
grounds with the phenotypes still are understood poorly. The
functional demands on the DAT1 regulation are seemingly
contradictory since the vital necessity of assuring the robust
functioning of the dopaminergic system coincides with the need for
plasticity and rapid fluctuations in the transcription rate. To better
understand the distinct sources and mechanisms that might
facilitate a phenotypic diversity of this magnitude, we compre-
hensively interrogated the sequence of the SLC6A3 gene applying
computational methods.
Our analysis revealed several unique features of the
human SLC6A3 gene sequence, including (1) a very high
frequency of SNPs (897, as in NCBI SNP) compared with the
SLC6A4 (441) and other brain-related genes, such as BDNF and
DRD4 (454 and 154 SNPs, respectively), that, depending on their
positional effect, engender various biological consequences; (2) the
abundance of VNTRs (more than 90 in the SLC6A3 gene body
alone), which is indicative of a tendency to open chromatin
structure in the locus, and increased accessibility to chromatin
modifiers; and (3) presence of intragenic CNVs. Most notable
characteristic of the human SLC6A3 is its high sensitivity of to
epigenetic regulation: in contrast to the relative enrichment in
GC nucleotides in the promoter-proximal region as occurs in most
human genes, the entire SLC6A3 locus has GC-bias sequence
composition (0.55) and comprises multiple CpG sites comprising
27 bona fide CGIs (CpG islands).
Importantly, our analysis revealed that the distinctive sequence
features of the SLC6A3 gene recognized by an array of regulatory
mechanisms are evolutionally recent. In fact, they are either
uniquely human or shared between human and primates. We
noted that the epigenetic sensitivity of the DAT1 gene increased
during evolution, and this process likely involves GC-bias gene
conversion (GCBC) that is viewed as a major force driving genome
evolution [137]. Indeed, whilst the mouse Slc6A3 gene has GC
content 0.46 and its promoter has no CpG island, promoter-
overlapping CpG island is present in the rat’s Slc6a3 gene;
furthering this tendency, the rhesus monkey’s SLC6A3 also has two
intragenic CpG islands. During evolution, the increase in demands
on the DAT1 expression might well have driven changes in the
gene sequence, expanding its sensitivity to the different regulatory
mechanisms. In this view, the GC-density and the number of CGIs
in the DAT gene might co-evolve with the growing role of epigenetic
mechanisms in its control. In other words, the evolutional drift of
the SLC6A3 sequence towards accumulating GC-nucleotides
might reflect its enhancing epigenetic potential, needed to
accommodate regulatory demands, as dictated by the increasingly
complex functions of the human brain.
The genomic regions experiencing GCBC are seen as
recombination hotspots [137] and, as such, the inherent instability
of the SLC6A3 locus could explain its unique sequence features and
regulatory attributes. These changes might be linked in time to the
genome rearrangement event that resulted in the translocation of a
syntenic block encompassing the DAT gene from the chromosome
13 (rodents) to the telomere-proximal region of the chromosome 5
(human and primates). In general, the propensity of genomic
regions to instability is deleterious characteristic, but, theoretically,
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es could be beneficial by allowing rapid adaptation [120,138,139].
Accordingly, the high variability of the DAT locus might support a
broad basis for phenotypic diversity, and thus, be advantageous.
Our detection of co-occurrence of the SNPs and the repeated
sequences with the CGIs (116 SNPs and 2 tandem repeats) infers
that the DAT1 might still be evolving.
Our observationthat there areseveralCNVsin the SLC6A3locus
is not unique; they are detected in several human genes [140] that
seemingly can asymptomatically tolerate this type of genetic
variations. Here the human CNV genes stand apart; evidence from
animal studies demonstrated that CNVs are depleted from
laboratory mouse strains during selective breeding [141]. Conse-
quently, it was postulated that that natural selection acts
discriminately among human CNV genes and thus, at least for a
subset of human genes, CNVs might confer adaptive benefits [140].
If propensity of the DAT1 locus to instability is high and can
give rise to frequent mutations, there must be other means to
compensate for potentially sub-optimal gene function resulting
from deleterious changes in its sequence. Considering the main
concept of systems biology, that emphasizes the biological
networks and hubs rather than a single specific process, we posit
that the multi-modality of the DAT expressional control with
multiple feed-back control loops ensures its functional robustness.
Our analysis suggests that the several arms of gene
regulatory network modulate the expression of the SLC6A3,
whereby differential engagements and/or combinatorial interplay
of different mechanisms of this network, DAT expression can be
robust and reliable yet plastic and adjustable to accommodate
environmental demands.
The novel regulatory paradigm for the SLC6A3 gene that built
upon our results might have direct practical implication.
Acknowledging that DAT regulation is far more complex than
that of average human gene implies that a comprehensive
investigation is needed to reliably predict functional changes
associated with the DAT polymorphism(s) and to infer possible
phenotypic manifestations of sequence variation(s),. That is, we
should consider broadening the scope of the future studies by
interrogating the multiple features of the SLC6A3 gene rather than
focusing on any single polymorphism in its sequence. Also, the
functional- and anatomical- diversity of the brain’s dopamine
system [61] must be accounted for. We elaborate this point taking
the 39-UTR VNTR polymorphism as an example. This
polymorphism was investigated in relation to a variety of
behavioral traits and diseases [142], [143,144], and the findings
of those research are conflicting. That is, the 10 repeats-allele (10/
10 genotype) in some studies, i.e., [145] was associated with a
lower translation rate and increased extracellular dopamine; while
in the others, i.e., [146] with higher efficacy of the DAT
translation in vitro and in vivo [147]. We suggest that considering
a genomic position of the respective polymorphism might resolve
this controversy. Indeed, the repeats number (the length of the
polymorphic region can affect exclusively the longer mRNAs since
the VNTR resides in the middle of 39-UTR. Evidently, the shorter
transcript isoforms (akin to S44625) are insensitive to this variation
since here the transcription is terminated upstream of the VNTR.
Considering the transcription bias towards preferential production
of shorter isoforms in specific brain regions, we expect that a
subset of brain functions executed through the specific brain
regions is inherently independent of the polymorphism. Converse-
ly, for the behavioral traits that rely on the transcription of long
mRNA isoforms, innate differences in transcripts stability and
conformational folding, subordinate to the genotype, will be
manifest phenotypically.
We want to reiterate that the analyses and observations
presented here are theoretical by nature and require experimental
validation. However, we believe, that they help broaden our
current understanding on the complex regulatory mechanisms
imbedded in the human DAT gene sequence.
Methods
The computational tools used to run the analyses and the
databases used to retrieve the sequences and to visualize genomic
features are listed in Table 1.
Supporting Information
Figure S1 Copy number variations in the SLC6A3 locus.
Information on validated structural variation maps of eight human
genomes with resolution at the sequence level for selected regions
is integrated in the UCSC Genome Browser. The CNVs in the
SLC6A3 genetic locus are visualized in the Browser. The orange
bar, indicating the longest deletion, encompasses two exons
(indicated by arrows).
Found at: doi:10.1371/journal.pone.0011067.s001 (0.10 MB EPS)
Figure S2 The SLC6A3 and the SLC6A4 regulatory regions.
Red bar in this visual display represents cisRED annotation-based
regulatory modules and predicted TFBSs are shown as brown
blocks. In the DAT1 (top) red bar is long and predicted TFBSs are
scattered over a long sequence stretch, whereas in the SERT
(bottom), red bar is composed of discrete units and TFBSs are
located within the TSS-proximal bar.
Found at: doi:10.1371/journal.pone.0011067.s002 (0.09 MB EPS)
Figure S3 Clusters of short interspersed repeats in the DAT1
39UTR. A - REPFIND program was used to identify clustered,
exact repeats within the 5 kb region located on the 39 - end of the
SLC6A3 that includes 39UTR. The program calculates a P-value
indicating the probability of finding such a concentration of that
particular repeat by chance for each repeat cluster found, and then
selects the cluster with the most significant P-value. Top ten out of
generated multiple repeated units with significant P-values
multiple repeats found by the program are shown at the panel
A. P-value of 8.18e-14 suggests that the closeness of these repeats is
not random, and together they form a unit likely to have
functional significance. B -CAG or CAG-containing motifs are the
most abundant motif in 39-UTRs of neuronal genes, therefore our
identification of multiple CAG motif clusters in the 39-UTR of the
SLC6A3 posits that translation of its mRNAs is likely occur near
the synaptic terminals. For this test, we used human 39-UTR
statistical background and P-value cutoff: 0.000001.
Found at: doi:10.1371/journal.pone.0011067.s003 (0.19 MB EPS)
Figure S4 Secondary structure of the SLC6A3 transcript
isoforms. A - The variation in the 39UTR region of the SLC6A3
results in production of different length mRNAs. We used the
GeneBee server to predict the secondary structure of RNAs
transcribed from the sequences containing 10 versus 9 repeats
which correspond to the most common allelic variations. As evident
from the figure, there the presence of the 10th repeated increment
profoundly changes the structure of the transcript. B - According to
analysis of dyad symmetries (hairpins) predicted for the respective
mRNAsequences (theSECentralClone Manager Suite7 program),
the folding structure and hairpin formation generated by the 39-
UTR sequences containing 9 and 10 repeats are strikingly different.
Wefoundthattheduplexesin9repeat’ssequencehavelongerstems
and higher energy than those from the 10 repeats (214.4 kcals
versus 7.4 kcals), suggesting that the 39-UTR VNTR might
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mRNA degradation, which depends on conservation of the hairpin
structures formed on mRNA 39-UTR ’s ends.
Found at: doi:10.1371/journal.pone.0011067.s004 (0.10 MB EPS)
Figure S5 Experimental histone methylation data for the
promoter region of the SLC6A3 and SLC6A4 genes. Compen-
dium of these data is integrated in the UCSC genome browser, so,
we retrieved the data on ‘‘active’’ histone modification mapped to
the promoter regions of two genes. Histone profiling of the
SLC6A3 (A) demonstrates lack of the acetylated histones and di-
and tri-methylated H3K4 (green arrows), whereas the profile of
the SLC6A4 regulatory region unequivocally reflects active status
of the chromatin (red arrows) (B).
Found at: doi:10.1371/journal.pone.0011067.s005 (0.17 MB EPS)
Figure S6 Prediction of the promoter region using Core-
Boost_HM. We used two algorithms of the program to assess
differences in the promoter prediction that depend on the
epigenetic sensitivity. A - For the SLC6A3, density scores
calculated for CpG-related promoters (upper panel) display the
highest peak overlapping with the putative TSS (red arrow).
Calculation under the assumption of CpG-independent promoter
fails to produce a peak near the canonical TSS; and the position of
the dominant peak is shifted downstream (green arrow). B - similar
analyses carried out for the SLC6A4 gene showed that the position
of the predicted promoter remains the same when CpG-
association is considered (upper panel, red arrow) or discounted
(lower panel, red arrow).
Found at: doi:10.1371/journal.pone.0011067.s006 (0.13 MB EPS)
Table S1 Known SNPs in the SLC6A3 locus.
Found at: doi:10.1371/journal.pone.0011067.s007 (0.20 MB
PDF)
Table S2 Tandem repeats in the SLC6A3 locus with a period
longer that 30 nt.
Found at: doi:10.1371/journal.pone.0011067.s008 (0.03 MB
PDF)
Table S3 Tandem repeats in the SLC6A4 locus.
Found at: doi:10.1371/journal.pone.0011067.s009 (0.04 MB
PDF)
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